Pfizer has announced a revised profit estimate for 2025, underpinned by a cost-cutting program, amid falling COVID product revenues and patent expirations. Shares rose 3.7% after the company reported a better-than-expected quarterly profit. However, Pfizer remains cautious, maintaining annual sales forecasts of between $61 billion and $64 billion, due to pandemic uncertainties and political pressure to cut drug prices.
Sources
Pfizer își majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri și al presiunilor politice din partea lui Trump
Pfizer își ridică prognoza de profit pentru 2025, mizând pe reduceri agresive de costuri și negocieri
Pfizer îşi majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri şi al presiunilor politice din partea lui Trump
Pfizer îşi majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri şi al presiunilor politice din partea lui Trump
Latest News
11:20
Petișor Peiu attacks Nicușor Dan / The AUR senator accuses him of poor governance and authoritarian excesses
11:10
COP31: The new draft climate decision does not mention fossil fuels, but calls for electrification
11:00
ANM issues warnings of blizzards, snowfall, and strong winds in several regions
10:57
Donald Trump once again calls Vladimir Putin his “friend,” despite criticism from Congress
10:46
The Ukrainian army reportedly struck the Rosgvardia headquarters in Krasnodar, Russia / The airport temporarily suspended flights
See more news